Design, synthesis, and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors

Journal of Medicinal Chemistry

Volumn 47, Issue 27, 2004, Pages 6749-6759

  Julémont, Fabien ^a   De Leval, Xavier ^a   Michaux, Catherine ^b   Renard, Jean François ^a   Winum, Jean Yves ^c   Montero, Jean Louis ^c   Damas, Jacques ^a   Dogné, Jean Michel ^a   Pirotte, Bernard ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF NAMUR   (Belgium)

^c UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; N (3 PHENYLAMINO 4 PYRIDINYL)TRIFLUOROMETHANESULFONAMIDE; NIMESULIDE; PYRIDINE DERIVATIVE; TRIFLUOROMETHANESULFONIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; EVALUATION; IC 50; NONHUMAN; PKA; POLYMERIZATION; RAT; REDUCTION; SUBSTITUTION REACTION;

CRYSTALLOGRAPHY, X-RAY; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG DESIGN; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 11144228243     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049480l     Document Type: Article

References (39)

1. 2 production in human gingival fibroblasts stimulated with interleukin-1beta and epidermal growth factor. Biochem. Biophys. Res. Commun. 1999, 257 (2), 528-532.
2. Smith, W.; De Witt, D.; Garavito, R. Structural, cellular, and molecular biology. Annu. Rev. Biochem. 2000, 69, 145-182.
3. Crofford, L.; Wilder, R.; Ristimaki, A.; Sano, H.; Remmers, E.; Epps, H.; Hla, T. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J. Clin. Invest. 1994, 93 (3), 1095-1101.
4. Mifflin, R.; Saada, J.; Di Mari, J.; Adegboyega, P.; Valentich, J.; Powell, D. Regulation of COX-2 expression in human intestinal myofibroblasts: mechanisms of IL-1-mediated induction. Am. J. Physiol: Cell Physiol. 2002, 282 (4), C824-834.
5. Cao, C.; Matsumura, K.; Shirakawa, N.; Maeda, M.; Jikihara, L; Watanabe, Y. Pyrogenic cytokines injected into the rat cerebral ventricle induce cyclooxygenase-2 in brain endothelial cells and also upregulate their receptors. Eur. J. Neurosci. 2001, 13 (9), 1781-1790.
6. Samad, T.; Moore, K.; Sapirstein, A.; Billet, S.; Allchorne, A.; Poole, S.; Bonventre, J.; Woolf, C. Interleukin-1beta-mediated induction of COX-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001, 410, 471-475.
7. lopez, L.; Alonso, A.; Bayon, Y.; Nieto, M.; Orduna, A.; Sanchez, M. Brucella lipopolysaccharides induce cyclooxygenase-2 expression in monocytic cells. Biochem. Biophys. Res. Commun. 2001, 289 (2), 372-375.
8. Devaux, Y.; Seguin, C.; Grosjean, S.; de Talance, N.; Camaeti, V.; Burlet, A.; Zannad, F.; Meistelman, C.; Mertes, P.; Longrois, D. Lipopolysaccharide-induced increase of prostaglandin E(2) is mediated by inducible nitric oxide synthase activation of the constitutive cyclooxygenase and induction of membrane-associated prostaglandin E synthase. J. Immunol. 2001, 167 (7), 3962-3971.
9. Futaki, N.; Takahashi, S.; Kitagawa, T.; Yamakawa, Y.; Tanaka, M.; Higuchi, S. Selective inhibition of cyclooxygenase-2 by NS-398 in endotoxin shock rats in vivo. Inflammation Res. 1997, 46 (12), 496-502.
10. Wallace, J. Pathogenesis of NSAID-induced gastroduodenal mucosal injury. Best Pract. Res. Clin. Gastroenterol. 2001, 15 (5), 691-703.
11. Cryer, B. Mucosal defense and repair. Role of prostaglandins in the stomach and duodenum. Gastroenterol. Clin. North Am. 2001, 30 (4), 877-894.
12. Coffey, R.; Hawkey, C.; Damstrup, L.; Graves-Deal, R.; Daniel, V.; Dempsey, P.; Chinery, R.; Kirkland, S.; DuBois, R.; Jetton, T.; Morrow, J. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc. Natl. Acad. Sci. U.S.A. 1997, 94 (2), 657-662.
13. Mitchell, J.; Evans, T. Cyclooxygenase-2 as a therapeutic target. Inflammation Res. 1998, 47 (S2), S88-S92.
14. Cao, Y.; Prescott, S. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J. Cell. Physiol. 2002, 190 (3), 279-286.
15. Chan, G.; Boyle, J.; Yang, E.; Zhang, F.; Sacks, P.; Shah, J.; Edelstein, D.; Soslow, R.; Koki, A.; Woerner, B.; Masferrer, J.; Dannenberg, A. Cyclooxygeaase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 1999, 59 (5), 991-994.
16. Half, E.; Tang, X.; Gwyn, K.; Sahin, A.; Wathen, K.; Sinicrope, F. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. 2002, 62 (6), 1676-1681.
17. Brodie, A.; Lu, Q.; Long, B.; Fulton, A.; Chen, T.; Macpherson, N.; DeJong, P.; Blankenstein, M.; Nortier, J.; Slee, P.; van de Ven, J.; van Grop, J.; Elbers, J.; Schipper, M.; Blijham, G.; Thijssen, J. Aromatase and COX-2 expression in human breast cancers. J. Steroid Biochem. Mol. Biol. 2001, 79, 41-47.
18. Yoshimatsu, K.; Altorki, N.; Golijanin, D.; Zhang, F.; Jakobsson, P.; Dannenberg, A.; Subbaramaiah, K. Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin. Cancer Res. 2001, 7(9), 2669-2674.
19. Dannenberg, A.; Altorki, N.; Boyle, J.; Lin, D.; Subbaramaiah, K. Inhibition of cyclooxygenase-2: an approach to preventing cancer of the upper aerodigestive tract. Ann. N.Y. Acad. Sci. 2001, 952, 109-115.
20. Taketo, M. COX-2 and colon cancer. Inflammation Res. 1998, 47, S112-S116.
21. Maekawa, M.; Sugano, K.; Sano, H.; Miyazaki, S.; Ushiama, M.: Fujita, S.; Gotoda, T.; Yokota, T.; Ohkura, H.; Kakizoe, T.; Sekiya, T, Increased expression of cyclooxygenase-2 to -1 in human colorectal cancers and adenomas, but not in hyperplastic polyps. Jpn. J. Clin. Oncol. 1998, 28 (7), 421-426.
22. Niijima, M.; Yamaguchi, T.; Ishihara, T.; Hara, T.; Kato, K.; Kondo, F.; Saisho, H. Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductal papillary-mucinous tumors of the pancreas. Cancer 2002, 94 (5), 1565-1373.
23. Lee, L.; Pan, C.; Cheng, C.; Chi, C.; Liu, T. Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Res. 2001, 21 (2B), 1291-1294.
24. Masferrer, J. Approach to angiogenesis inhibition based on cyclooxygenase-2. Cancer J. 2001, 7 (S3), S144-S150.
25. Sinicrope, F.; Half, E.; Morris, J.; Lynch, P.; Morrow, J.; Levin, B.; Hawk, E.; Cohen, D.; Ayers, G.; Stephens, L. Familial Adenomatous Polyposis Study Group. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol., Biomarkers Prev. 2004, 13 (6), 920-927.
26. Supuran, C.; Casini, A.; Mastrolorenzo, A.; Scozzafava, A. COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents. Mini-Rev. Med. Chem. 2004, 4, 625-632.
27. Danhardt, G.; Kiefer, W. Cyclooxygenase inhibitors current status and future prospects. Eur. J. Med. Chem. 2001, 36, 109-126.
28. Julemont, F.; de Leval, X.; Michaux, C.; Damas, J.; Charlier, C.; Durant, F.; Pirotte, B.; Dogne, J. Spectral and Crystallographic Study of Pyridinic Analogues of Nimesulide: Determination of the Active Form of Methanesulfonamides as COX-2 Selective Inhibitors. J. Med. Chem. 2002, 45, 5182-5185.
29. Michaux, C.; Charlier, C. Structural approach for COX-2 inhibition. Mini-Rev. Med. Chem. 2004, 4, 603-615.
30. Kurumbail, R. G.; Stevens, A. M.; Gierse, J. K.; McDonald, J. J.; Stegeman, R. A.; Pak, J. Y.; Gildehaus, D.; Miyashiro, J. M.; Penning, T. D.; Seibert, K.; Isakson, P. C.; Stallings, W. C. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996, 384, 644-648.
31. Garcia-Nieto, R.; Pérez, C.; Gago, F. Automated docking and molecular dynamics simulations of nimesulide in the cyclooxygenase active site of human prostaglandin-endoperoxide synthase-2 (COX-2). J. Comput.-Aided Mol. Des. 2000, 14, 147-160.
32. Altomare, A.; Burla, M. C.; Camalli, M.; Cascarano, G.; Giacovazzo, C.; Guagliardi, A.; Moliterni, A. G. G.; Polidori, G.; Spagna, R, SIR97: a new tool for crystal structure determination and refinement. J. Appl. Crystallogr. 1999, 32, 115-119.
33. Sheldrick, G. M. SHELXL97: Program for the Refinement of Crystal Structures; Institut für Anorganische Chemie der Universität Göttingen: Göttingen, Germany, 1997.
34. Biosyrn/MSI. Insight II 97.0: HOMOLOGY; Molecular Simulations Inc.: San Diego, CA, 1997.
35. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. GOLU, version 1.2, Astex Technology: Cambridge, U.K., 2001.
36. Hart, T. N.; Ness, S. R. Dockvision, version 1.0.3, Alberta, CA, 1998.
37. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
38. Discovers, version 2.98, Accelrys Inc.: San Diego, CA, 1998.
39. Honig, B.; Sharp, K. A.; Yang, A.-S. Macroscopic models of aqueous solutions: biological and chemical applications. J. Phys. Chem. 1993, 97, 1101-1109.